Emigrant Capital

Emigrant Capital Corp. is a private equity firm based in New York, specializing in investments in middle-market companies. As the private equity arm of Emigrant Savings Bank, it focuses on various investment strategies, including recapitalization, management buyouts, corporate acquisitions, and investments in distressed or turnaround situations. The firm primarily targets environmental products and services, software, outsourced business services, geriatric healthcare, light manufacturing, and scalable business services. Emigrant Capital typically invests between $5 million and $25 million in companies with revenues ranging from $15 million to $100 million and EBITDA between $2 million and $12 million. It employs a range of investment structures, including traditional equity, hybrid debt/equity securities, mezzanine financing, and various forms of debt. Founded in 1999, Emigrant Capital aims to establish majority or significant minority stakes in its investment targets and works closely with management teams to enhance value.

Jordan Campbell

Analyst

Christopher Hammond

Executive Vice President

Duncan Rogers

Associate

Rafael Romero

Principal

Chris Staudt

President

Bill Staudt

Vice Chairman

10 past transactions

Affiniti

Seed Round in 2024
Affiniti is a financial services company focused on enhancing banking infrastructure for small businesses in America. The company offers a specialized finance platform that provides industry-tailored credit cards, cash-back reward programs, and vendor discounts. These features help businesses save on expenses while managing their financial operations more effectively. Affiniti's platform enables users to control spending by setting permissions and limits for team members, while also ensuring accountability through expense tracking, memos, and receipts. This approach not only supports small businesses in managing their finances but also delivers valuable rewards and features tailored to their specific industries.

Frequency Therapeutics

Series B in 2019
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

Golf

Acquisition in 2018
Golf.com, LLC is a prominent online platform dedicated to serving the golf community by providing comprehensive coverage of major golf tours, including the PGA, LPGA, Champions', and Nationwide tours. The platform features live leaderboard results, news, and unique commentary, catering to both professional and recreational golfers. It also offers innovative services such as Play With The Pros, an artificial intelligence technology that connects golfers with instructors for personalized swing analysis and instruction. Additionally, Golf.com provides a fee-based membership program that allows golfers to establish and maintain a USGA Handicap Index while tracking their performance. Based in Raleigh, North Carolina, Golf.com is recognized for its commitment to enhancing the golf experience through informative content and community engagement.

Frequency Therapeutics

Series A in 2017
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

GroundLink

Series A in 2008
GroundLink operates a car booking platform that offers convenient transportation services across the United States and in over 110 countries. The company focuses on providing an easy-to-use reservation system for both consumer and corporate clients, allowing them to book executive car services online or through mobile apps. GroundLink guarantees timely arrivals, promising that if a driver is late, the next ride is free. Users can track their drivers in real-time and receive digital receipts via email, eliminating the need for paper vouchers. By leveraging technology, GroundLink aims to innovate the travel experience and ensure reliable, efficient transportation.

Lev Pharmaceuticals

Venture Round in 2006
Lev Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Its products include C1-INH that is used for the treatment of hereditary angioedema. The company was founded in 2003 and is based in New York, New York. As of October 21, 2008, Lev Pharmaceuticals, Inc. operates as a subsidiary of ViroPharma Inc.

Global Learning Systems

Seed Round in 2006
Global Learning Systems, LLC specializes in cybersecurity awareness training aimed at enhancing organizational resilience and awareness. Established in 2006 and headquartered in Clarksville, Maryland, with an additional office in Lynchburg, Virginia, the company serves both enterprises and small to medium businesses. Its key offerings include the Human Firewall 2.0 training program, phishing simulations, the GLS OnDemand portal, and customized course development. Additionally, Global Learning Systems provides HR and compliance training services, ensuring that clients can effectively meet regulatory requirements. With over 25 years of experience, the company delivers a client-focused approach, offering services in over 25 languages, thereby supporting organizations in developing their human capital and addressing various business challenges through integrated learning solutions. Global Learning Systems operates as a subsidiary of Bancroft Technology Group Inc.

Boylan Bottling

Venture Round in 2003
Boylan Bottling Co., Inc. is a producer of hand-crafted sodas, established in 1891 and based in Moonachie, New Jersey. The company specializes in a variety of flavors, including ginger ale, root beer, black cherry, creme soda, orange, grape, and birch beer, using cane sugar for many of its offerings. In addition to traditional sodas, Boylan Bottling produces diet versions of its popular flavors. The company also provides seltzers and mixers, along with branded merchandise such as coasters and wooden crates. Boylan Bottling markets its products through various retailers and online platforms.

Intralinks

Venture Round in 2001
Intralinks Holdings, Inc. is a technology company that specializes in software-as-a-service (SaaS) solutions for secure enterprise content collaboration, both domestically and internationally. Founded in 1996 and based in New York, Intralinks provides a cloud-based platform that facilitates the management, control, and exchange of sensitive information within and between organizations. Its product offerings include Intralinks Dealspace for virtual deal rooms, Intralinks Studyspace for sharing confidential information, and Intralinks VIA for enterprise content sharing. The company serves a diverse range of industries, including financial services, life sciences, technology, and manufacturing, and caters to enterprises, financial institutions, and governmental agencies. Intralinks distributes its solutions directly through a dedicated sales team and indirectly via a network of channel partners and customer referrals. The company has undergone several changes in ownership and name, most recently becoming a subsidiary of SS&C Technologies Holdings, Inc.

RealNames

Series D in 2000
RealNames is an online platform that provides internet naming solutions and a navigation system designed to simplify internet access for users. Founded in 1996 by Keith Teare and headquartered in San Carlos, California, with additional offices in major cities worldwide, RealNames offers a system that utilizes keywords for HTTP protocol navigation. This innovative approach enhances user experience by streamlining the process of finding websites. The company's services cater to a diverse clientele, including businesses of various sizes, advertising agencies, internet service providers, online services, search engines, and directory services. Additionally, RealNames offers ad-free email solutions compatible with popular email programs and accessible via web browsers and mobile devices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.